These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 3524789)

  • 21. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
    Büchner T; Urbanitz D; Hiddemann W; Rühl H; Ludwig WD; Fischer J; Aul HC; Vaupel HA; Kuse R; Zeile G
    J Clin Oncol; 1985 Dec; 3(12):1583-9. PubMed ID: 3906048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group.
    Zittoun R; Jehn U; Fière D; Haanen C; Löwenberg B; Willemze R; Abels J; Bury J; Peetermans M; Hayat M
    Blood; 1989 Mar; 73(4):896-906. PubMed ID: 2645950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Remission maintenance for acute nonlymphocytic leukemia: cytosine arabinoside plus 6-thioguanine versus a sequence of drug regimens.
    Presant CA; Berger NA; Klahr C; Phillips GL
    Cancer; 1980 Jul; 46(1):22-8. PubMed ID: 6930320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant specific immunotherapy in maintenance treatment of adult acute non-lymphocytic leukemia.
    Rühl H; Fülle HH; Koeppen KM; Schwerdtfeger R
    Klin Wochenschr; 1981 Nov; 59(21):1189-93. PubMed ID: 6947118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial.
    Rees JK; Gray RG; Swirsky D; Hayhoe FG
    Lancet; 1986 Nov; 2(8518):1236-41. PubMed ID: 2878130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG).
    Ohno R; Kobayashi T; Morishima Y; Hiraoka A; Imai K; Asoh N; Tsubaki K; Tomonaga M; Takahashi I; Kodera K
    Leukemia; 1992; 6 Suppl 2():92-5. PubMed ID: 1578954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
    Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
    Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternating pulses of vincristine-prednisone with cytarabine-cyclophosphamide versus vincristine-prednisone in the maintenance therapy of acute lymphoblastic leukemia.
    Sackmann Muriel F; Svarch E; Pavlovsky S; Bustelo P; Giuntoli J; Vergara B; Garay G; Eppinger-Helft M; Kvicala R; Dibar E
    Cancer Treat Rep; 1984 Apr; 68(4):581-6. PubMed ID: 6370428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
    Archimbaud E; Fiere D; Treille-Ritouet D; Adeleine P; Guyotat D; Sebban C; Vuvan H; Viala JJ
    Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
    Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
    Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA.
    Mandelli F; Vegna ML; Avvisati G; Amadori S; Spadea A; Cacciola E; Cantore N; De Laurenzi A; De Rosa C; Fioritoni G
    Ann Hematol; 1992 Apr; 64(4):166-72. PubMed ID: 1581404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
    Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
    Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of childhood acute nonlymphocytic leukemia with high-dose cytosine arabinoside, 6-thioguanine, and doxorubicin without maintenance therapy: pilot study ANLL-80 of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; Hhlen K; Colly LP; Vossen JM
    Pediatr Hematol Oncol; 1988; 5(2):93-102. PubMed ID: 3152962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia.
    Rohatiner AZ; Bassan R; Raimondi R; Amess JA; Arnott S; Personen A; Rodeghiero F; Barbui T; Bradburn MJ; Carter M; Lister TA
    Ann Oncol; 2000 Aug; 11(8):1007-15. PubMed ID: 11038038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential therapy for induction and maintenance of remission in acute myeloblastic leukemia.
    Eppinger-Helft M; Pavlovsky S; Suarez A; Muriel FS; Hidalgo G; Pavlovsky A; Vilaseca G
    Cancer; 1975 Feb; 35(2):347-53. PubMed ID: 1053936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.
    Herzig RH; Lazarus HM; Wolff SN; Phillips GL; Herzig GP
    J Clin Oncol; 1985 Jul; 3(7):992-7. PubMed ID: 3894588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.
    Zuhrie SR; Harris R; Freeman CB; MacIver JE; Geary CG; Delamore IW; Tooth JA
    Br J Cancer; 1980 Mar; 41(3):372-7. PubMed ID: 6992827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
    Linkesch W; Michlmayr G; Gerhartz H; Illinger H; König H; Düllmann J; Keilhauer R; Moldrzyk D
    Onkologie; 1989 Feb; 12(1):8-10. PubMed ID: 2654791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.